BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 9126702)

  • 1. The pharmacology of meropenem, a new carbapenem antibiotic.
    Craig WA
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S266-75. PubMed ID: 9126702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meropenem: a new carbapenem antimicrobial.
    Pryka RD; Haig GM
    Ann Pharmacother; 1994 Sep; 28(9):1045-54. PubMed ID: 7803882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Preclinical evaluation of meropenem, a new parenteral carbapenem].
    Edwards JR
    New Microbiol; 1995 Oct; 18 Suppl():19S-31S. PubMed ID: 8574929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients.
    Moon YS; Chung KC; Gill MA
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S249-55. PubMed ID: 9126700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.
    Wiseman LR; Wagstaff AJ; Brogden RN; Bryson HM
    Drugs; 1995 Jul; 50(1):73-101. PubMed ID: 7588092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
    Ong CT; Kuti JL; Nicolau DP;
    Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of meropenem in the treatment of serious infections in children: review of the current literature.
    Arrieta A
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S207-12. PubMed ID: 9126695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbapenems and monobactams: imipenem, meropenem, and aztreonam.
    Hellinger WC; Brewer NS
    Mayo Clin Proc; 1999 Apr; 74(4):420-34. PubMed ID: 10221472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meropenem, a new carbapenem antibiotic.
    Fish DN; Singletary TJ
    Pharmacotherapy; 1997; 17(4):644-69. PubMed ID: 9250544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2009].
    Yamaguchi K; Ishii Y; Iwata M; Watanabe N; Shinagawa M; Yasujima M; Suwabe A; Kuroda M; Kaku M; Kitagawa M; Kanemitsu K; Imafuku Y; Murakami M; Yomodu S; Taniguchi N; Yamada T; Nomura F; Kanno H; Maesaki S; Hashikita G; Kondo S; Misawa S; Horiuchi H; Tazawa Y; Nakashima H; Takemura H; Okada M; Horikawa Y; Maekawa M; Nagura O; Yagi T; Baba H; Ishigo S; Fujita N; Komori T; Ichiyama S; Yamanaka K; Murata Y; Matsuo S; Kohno H; Kawano S; Kinoshita S; Taminato T; Negayama K; Murase M; Miyamoto H; Kusano N; Nose M; Yokozaki M; Itaha H; Matsunaga A; Yoshimura H; Kohno S; Yanagihara K; Matsuda J; Saikawa T; Hiramatsu K
    Jpn J Antibiot; 2011 Apr; 64(2):53-95. PubMed ID: 21721247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meropenem: a new, extremely broad spectrum beta-lactam antibiotic for serious infections in pediatrics.
    Bradley JS
    Pediatr Infect Dis J; 1997 Mar; 16(3):263-8. PubMed ID: 9076812
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative review of imipenem/cilastatin versus meropenem.
    Salmon-Rousseau A; Martins C; Blot M; Buisson M; Mahy S; Chavanet P; Piroth L
    Med Mal Infect; 2020 Jun; 50(4):316-322. PubMed ID: 32035719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo antibacterial activities of meropenem, a new carbapenem antibiotic.
    Harabe E; Kawai Y; Kanazawa K; Otsuki M; Nishino T
    Drugs Exp Clin Res; 1992; 18(2):37-46. PubMed ID: 1644010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro antibacterial activity of meropenem, a new carbapenem: European data].
    Debbia EA; Marchese A; Pesce A; Schito GC
    New Microbiol; 1995 Oct; 18 Suppl():1S-17S. PubMed ID: 8574928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of a new carbapenem antibiotic, BO-2727, with potent antipseudomonal activity.
    Nakagawa S; Hashizume T; Matsuda K; Sanada M; Okamoto O; Fukatsu H; Tanaka N
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2756-9. PubMed ID: 8109950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of meropenem (SM-7338), imipenem, and five other antibiotics against anaerobic clinical isolates.
    Murray PR; Niles AC
    Diagn Microbiol Infect Dis; 1990; 13(1):57-61. PubMed ID: 2331851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The growth-inhibitory properties of meropenem against anaerobes of clinical importance.
    Watt B; Naden M
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():119-24. PubMed ID: 2808203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meropenem: a review of its use in patients in intensive care.
    Hurst M; Lamb HM
    Drugs; 2000 Mar; 59(3):653-80. PubMed ID: 10776838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers.
    Pitkin DH; Sheikh W; Nadler HL
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S238-48. PubMed ID: 9126699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.